Kepala Batas

Researchers are evaluating how well elacestrant works compared to standard endocrine therapy in adults with node-positive, Estrogen Receptor-positive (ER+), Human Epidermal Growth Factor-2 negative (HER2-) early breast cancer who are at high risk of the cancer returning. This is a Phase 3 global, multicenter, randomized, open-label study focusing on participants who have had early invasive breast cancer removed and meet specific receptor and risk criteria. The study aims to understand which treatment better prevents invasive breast cancer over up to five years. Participants will receive either elacestrant or one of several standard endocrine therapies, including anastrozole, letrozole, exemestane, or tamoxifen, all given as oral tablets. Treatments will be administered according to the study plan, with careful monitoring throughout the trial. The study includes adults who have already received between 24 and 60 months of prior endocrine therapy, with or without certain inhibitors, and who have completed or stopped these treatments as required. During the study, participants will be monitored for invasive breast cancer-free survival for up to five years. Researchers will perform regular assessments to track treatment effects, side effects, and cancer recurrence. The study also includes safety monitoring and may involve additional tests or evaluations as needed to ensure participant well-being throughout the trial.

Digital eye strain (DES), also known as computer vision syndrome, includes eye and vision problems caused by prolonged use of digital devices like computers, tablets, and smartphones. This condition is common among all age groups and is especially concerning in children due to their increasing screen time. Researchers are investigating whether dietary supplementation with astaxanthin, a natural antioxidant pigment, can help reduce DES symptoms, improve health complaints related to blue light exposure, and enhance cognitive function and quality of life in school-age children. The study compares two groups of children with digital eye strain: one receiving a daily oral astaxanthin capsule and the other a placebo olive oil capsule. Both treatments are given once daily for 24 weeks. The trial is randomized, double-blind, and placebo-controlled, meaning neither participants nor researchers know who receives astaxanthin or placebo during the study. Participants will be evaluated at the start, 12 weeks, and 24 weeks, with researchers measuring changes in eye strain symptoms using a specific questionnaire. The study will also monitor the children's overall health and any side effects. This approach aims to understand if astaxanthin supplementation can safely improve symptoms and quality of life related to digital eye strain in children over the 24-week period.